Literature DB >> 21680619

Inverse association of plasma level of high-density lipoprotein cholesterol with intracerebral hemorrhage.

Xinguo Wang1, Shaohua Li, Yongyi Bai, Xiaohan Fan, Kai Sun, Jizheng Wang, Rutai Hui.   

Abstract

This study aimed to investigate whether plasma levels of HDL cholesterol (HDL-C) were associated with the risk of intracerebral hemorrhage (ICH). Plasma HDL-C was determined via enzymatic methods, and ICH was ascertained via medical history, physical examination, and brain imaging (computed tomography or magnetic resonance imaging). The multivariable logistic regression model was used to calculate the odds ratios (OR) and 95% confidence intervals (CI) of ICH according to levels of plasma cholesterol. A total of 170 patients with ICH were identified from 6,046 participants. After adjustment for conventional cardiovascular risk factors, the OR was 2.06 (95% CI, 1.25-3.12; P < 0.01) for participants in the first tertile of HDL-C levels (<1.38 mmol/l) and 1.13 (95% CI, 0.72-1.78; P = 0.59) for participants in the second tertile (1.38-1.64 mmol/l), compared with participants in the third tertile (∩≥1.65 mmol/l). Subgroup analysis indicated that the detrimental effects of HDL-C were more significant in men and lean participants than in their corresponding controls, independent of hypertension. The results presented herein indicate that low plasma HDL-C (<1.38 mmol/l) may be associated with risk of ICH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680619      PMCID: PMC3151695          DOI: 10.1194/jlr.P008755

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  42 in total

1.  Editorial comment--Minor risk factors for intracerebral hemorrhage: the jury is still out.

Authors:  Amanda G Thrift
Journal:  Stroke       Date:  2003-07-03       Impact factor: 7.914

2.  High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

Authors:  Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

3.  HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.

Authors:  Paul M Ridker; Jacques Genest; S Matthijs Boekholdt; Peter Libby; Antonio M Gotto; Børge G Nordestgaard; Samia Mora; Jean G MacFadyen; Robert J Glynn; John J P Kastelein
Journal:  Lancet       Date:  2010-07-23       Impact factor: 79.321

4.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids.

Authors:  M Navab; S Y Hama; G P Hough; G Subbanagounder; S T Reddy; A M Fogelman
Journal:  J Lipid Res       Date:  2001-08       Impact factor: 5.922

5.  Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe.

Authors:  M L Bots; P C Elwood; Y Nikitin; J T Salonen; A Freire de Concalves; D Inzitari; J Sivenius; V Benetou; J Tuomilehto; P J Koudstaal; D E Grobbee
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

6.  HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men.

Authors:  S G Wannamethee; A G Shaper; S Ebrahim
Journal:  Stroke       Date:  2000-08       Impact factor: 7.914

7.  Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.

Authors:  Terry L Lewis; Dongfeng Cao; Hailin Lu; Robert A Mans; Yan Ru Su; Lisa Jungbauer; MacRae F Linton; Sergio Fazio; Mary Jo LaDu; Ling Li
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

Review 8.  Risk factors for intracerebral hemorrhage in the general population: a systematic review.

Authors:  M J Ariesen; S P Claus; G J E Rinkel; A Algra
Journal:  Stroke       Date:  2003-07-03       Impact factor: 7.914

9.  High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study.

Authors:  Yoshiyuki Soyama; Katsuyuki Miura; Yuko Morikawa; Muneko Nishijo; Yumiko Nakanishi; Yuchi Naruse; Sadanobu Kagamimori; Hideaki Nakagawa
Journal:  Stroke       Date:  2003-03-13       Impact factor: 7.914

10.  Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Authors:  Pierre Amarenco; Larry B Goldstein; Alfred Callahan; Henrik Sillesen; Michael G Hennerici; Blair J O'Neill; Amy E Rudolph; Lisa Simunovic; Justin A Zivin; K M A Welch
Journal:  Atherosclerosis       Date:  2008-09-18       Impact factor: 5.162

View more
  1 in total

1.  A pooled analysis of the association of isolated low levels of high-density lipoprotein cholesterol with cardiovascular mortality in Japan.

Authors:  Takumi Hirata; Daisuke Sugiyama; Shin-Ya Nagasawa; Yoshitaka Murakami; Shigeyuki Saitoh; Akira Okayama; Hiroyasu Iso; Fujiko Irie; Toshimi Sairenchi; Yoshihiro Miyamoto; Michiko Yamada; Shizukiyo Ishikawa; Katsuyuki Miura; Hirotsugu Ueshima; Tomonori Okamura
Journal:  Eur J Epidemiol       Date:  2016-10-05       Impact factor: 8.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.